Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Other Accumulated Expenses for 14 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 41.66% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, up 41.66%, and an annual FY2025 reading of $1.8 million, down 41.69% over the prior year.
  • Other Accumulated Expenses was $2.1 million for Q4 2025 at Enanta Pharmaceuticals, up from $1.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $14.4 million in Q1 2022 and bottomed at $867000.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $3.5 million, with a median of $2.3 million recorded in 2025.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 1295.16% in 2022, then plummeted 93.98% in 2023.
  • Year by year, Other Accumulated Expenses stood at $1.1 million in 2021, then soared by 541.91% to $6.9 million in 2022, then tumbled by 45.98% to $3.7 million in 2023, then plummeted by 60.88% to $1.4 million in 2024, then surged by 41.66% to $2.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ENTA at $2.1 million in Q4 2025, $1.8 million in Q3 2025, and $2.4 million in Q2 2025.